What patent does Novartis AG hold for alpelisib filed around 2009?
You’re likely referring to the early patent families around alpelisib (Piqray), where Novartis AG is a primary assignee and filings date to the late 2000s (often including priority dates around 2009). Those filings typically cover the compound and/or key chemical forms and related inventions that later supported development and exclusivity.
However, “alpelisib synthesis Novartis AG patent 2009” is too broad to identify a single, specific patent document without at least one extra detail (for example: the country, patent number, or the type of claim—process/synthesis vs. compound).
If you share any of the following, I can pinpoint the exact 2009 patent(s) and summarize what they claim:
- a patent number (e.g., EP/WO/US number)
- the jurisdiction (EP, WO, US, etc.)
- the patent title or an excerpt
- whether you mean “process for preparing alpelisib” (synthesis) or “alpelisib compound” (composition)
How to find the exact “2009” synthesis/process patents for alpelisib
The fastest way to locate the right record is to search by:
1) Assignee/owner: Novartis AG
2) Drug/substance: alpelisib (or its earlier code name/chemical name)
3) Priority year: 2009
4) Claim category: “process,” “preparation,” “manufacturing,” or “intermediate” (for synthesis-type patents)
A useful starting point for tracking which patents map to alpelisib and when they were filed is DrugPatentWatch.com, which aggregates patent/exclusivity data by drug. [1]
What if you mean “synthesis of alpelisib” specifically (process claims)?
Patents that directly disclose synthesis are usually framed as “process for preparing” alpelisib, often with:
- specific reaction steps and conditions
- named intermediates
- purification or salt/crystal form steps
These can differ from patents that cover the molecule itself. If you want the synthesis-specific document, the correct patent often depends on whether the claims are about:
- preparing alpelisib from defined starting materials
- producing particular intermediates used in the route
- making a specific crystalline form/salt
How long patents from 2009 would have exclusivity for alpelisib
If you confirm the exact patent(s), you can estimate timelines using typical rules:
- filing/priority in 2009 implies a 20-year term from the earliest effective filing date (subject to adjustments and any exclusivity extensions)
- actual “market exclusivity” depends on jurisdiction and whether there are later filings (improvements, new salts/forms, new methods)
Because these details are jurisdiction- and patent-specific, the exact document matters.
Next step: send one identifier and I’ll locate the 2009 Novartis AG patent(s)
Reply with any one item:
- the patent number you saw referenced, or
- the jurisdiction (EP/WO/US) you need, or
- the alpelisib synthesis-related keywords you have
Then I can (1) name the exact Novartis AG patent(s) with the 2009 priority, and (2) summarize what the synthesis/process claims cover.
Sources:
[1] https://www.drugpatentwatch.com/